Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Brain Injury Awareness Month: New Hope With Psychedelic Medicine
Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences announced the successful completion of a 28-day toxicology study for BMB-101.